Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Glanzmann thrombasthenia: genetic basis and clinical correlates.

Perez Botero J, Lee K, Branchford BR, Bray PF, Freson K, Lambert MP, Luo M, Mohan S, Ross JE, Bergmeier W, Di Paola J; ClinGen Platelet Disorder Variant Curation Expert Panel.

Haematologica. 2020 Mar 5. pii: haematol.2018.214239. doi: 10.3324/haematol.2018.214239. [Epub ahead of print]

2.

ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants.

Luo X, Feurstein S, Mohan S, Porter CC, Jackson SA, Keel S, Chicka M, Brown AL, Kesserwan C, Agarwal A, Luo M, Li Z, Ross JE, Baliakas P, Pineda-Alvarez D, DiNardo CD, Bertuch AA, Mehta N, Vulliamy T, Wang Y, Nichols KE, Malcovati L, Walsh MF, Rawlings LH, McWeeney SK, Soulier J, Raimbault A, Routbort MJ, Zhang L, Ryan G, Speck NA, Plon SE, Wu D, Godley LA.

Blood Adv. 2019 Oct 22;3(20):2962-2979. doi: 10.1182/bloodadvances.2019000644.

3.

Inheritance of the CENP-A chromatin domain is spatially and temporally constrained at human centromeres.

Ross JE, Woodlief KS, Sullivan BA.

Epigenetics Chromatin. 2016 May 31;9:20. doi: 10.1186/s13072-016-0071-7. eCollection 2016.

4.

Multicenter Investigation of Gepotidacin (GSK2140944) Agar Dilution Quality Control Determinations for Neisseria gonorrhoeae ATCC 49226.

Jones RN, Fedler KA, Scangarella-Oman NE, Ross JE, Flamm RK.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4404-6. doi: 10.1128/AAC.00527-16. Print 2016 Jul.

5.

Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).

Flamm RK, Mendes RE, Hogan PA, Streit JM, Ross JE, Jones RN.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2273-80. doi: 10.1128/AAC.02803-15. Print 2016 Apr.

6.

Determination of Disk Diffusion and MIC Quality Control Guidelines for Solithromycin, a Novel Fluoroketolide Antibacterial, against Neisseria gonorrhoeae.

Riedel S, Ross JE, Farrell DJ, Flamm RK, Jones RN.

J Clin Microbiol. 2015 Dec;53(12):3888-90. doi: 10.1128/JCM.02250-15. Epub 2015 Sep 16.

7.

Initial broth microdilution quality control guidelines for Debio 1452, a FabI inhibitor antimicrobial agent.

Ross JE, Flamm RK, Jones RN.

Antimicrob Agents Chemother. 2015 Nov;59(11):7151-2. doi: 10.1128/AAC.01690-15. Epub 2015 Aug 31. No abstract available.

8.

Hybrid Diphenylalkyne-Dipeptide Oligomers Induce Multistrand β-Sheet Formation.

Ross JE, Knipe PC, Thompson S, Hamilton AD.

Chemistry. 2015 Sep 21;21(39):13518-21. doi: 10.1002/chem.201502690. Epub 2015 Aug 11.

PMID:
26264561
9.

In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program.

Flamm RK, Mendes RE, Hogan PA, Ross JE, Farrell DJ, Jones RN.

Diagn Microbiol Infect Dis. 2015 Apr;81(4):283-9. doi: 10.1016/j.diagmicrobio.2014.12.009. Epub 2014 Dec 30.

PMID:
25633420
10.

β-Strand mimetic foldamers rigidified through dipolar repulsion.

German EA, Ross JE, Knipe PC, Don MF, Thompson S, Hamilton AD.

Angew Chem Int Ed Engl. 2015 Feb 23;54(9):2649-52. doi: 10.1002/anie.201410290. Epub 2015 Jan 19.

PMID:
25599889
11.

Quality control MIC ranges used for telavancin with application of a revised CLSI reference broth microdilution method.

Ross JE, Mendes RE, Jones RN.

J Clin Microbiol. 2014 Sep;52(9):3399-401. doi: 10.1128/JCM.01210-14. Epub 2014 Jun 11.

12.

Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent.

Ross JE, Scangarella-Oman NE, Flamm RK, Jones RN.

J Clin Microbiol. 2014 Jul;52(7):2629-32. doi: 10.1128/JCM.00656-14. Epub 2014 Apr 23.

13.

Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States.

Mendes RE, Flamm RK, Hogan PA, Ross JE, Jones RN.

Antimicrob Agents Chemother. 2014;58(2):1243-7. doi: 10.1128/AAC.02112-13. Epub 2013 Dec 9.

14.

Risk for transmission of Naegleria fowleri from solid organ transplantation.

Roy SL, Metzger R, Chen JG, Laham FR, Martin M, Kipper SW, Smith LE, Lyon GM 3rd, Haffner J, Ross JE, Rye AK, Johnson W, Bodager D, Friedman M, Walsh DJ, Collins C, Inman B, Davis BJ, Robinson T, Paddock C, Zaki SR, Kuehnert M, DaSilva A, Qvarnstrom Y, Sriram R, Visvesvara GS.

Am J Transplant. 2014 Jan;14(1):163-71. doi: 10.1111/ajt.12536. Epub 2013 Nov 26.

15.

Streptococcus sanguinis isolate displaying a phenotype with cross-resistance to several rRNA-targeting agents.

Mendes RE, Deshpande LM, Kim J, Myers DS, Ross JE, Jones RN.

J Clin Microbiol. 2013 Aug;51(8):2728-31. doi: 10.1128/JCM.00757-13. Epub 2013 May 22.

16.

Educational antimicrobial susceptibility testing as a critical component of microbiology laboratory proficiency programs: American Proficiency Institute results for 2007-2011.

Jones RN, Glick T, Sader HS, Flamm RK, Ross JE, Rhomberg PR, Edson DC.

Diagn Microbiol Infect Dis. 2013 Apr;75(4):357-60. doi: 10.1016/j.diagmicrobio.2013.01.027. Epub 2013 Mar 6.

PMID:
23481025
17.

An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011.

Flamm RK, Mendes RE, Ross JE, Sader HS, Jones RN.

Diagn Microbiol Infect Dis. 2013 Jun;76(2):206-13. doi: 10.1016/j.diagmicrobio.2013.01.025. Epub 2013 Mar 9.

PMID:
23478031
18.

Determination of disk diffusion and MIC quality control guidelines for GSK2251052: a novel boron-containing antibacterial.

Ross JE, Scangarella-Oman N, Jones RN.

Diagn Microbiol Infect Dis. 2013 Apr;75(4):437-9. doi: 10.1016/j.diagmicrobio.2013.01.007. Epub 2013 Feb 23.

PMID:
23461830
19.

Letter to the editor.

Ross JE.

J S C Med Assoc. 2013 Mar-Apr;109(1):20. No abstract available.

PMID:
24902330
20.

Evaluation of coagulation factors and platelet function from an off-line modified ultrafiltration technique for post-cardiopulmonary bypass circuit blood recovery.

Beckmann S, Lynn P, Miller S, Harris R, DiMarco RF, Ross JE.

Perfusion. 2013 May;28(3):214-22. doi: 10.1177/0267659112470710. Epub 2012 Dec 27.

PMID:
23271047
21.

Linezolid surveillance results for the United States: LEADER surveillance program 2011.

Flamm RK, Mendes RE, Ross JE, Sader HS, Jones RN.

Antimicrob Agents Chemother. 2013 Feb;57(2):1077-81. doi: 10.1128/AAC.02112-12. Epub 2012 Dec 17.

22.

ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries.

Flamm RK, Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN.

J Chemother. 2012 Dec;24(6):328-37. doi: 10.1179/1973947812Y.0000000039.

PMID:
23174097
23.

Disk diffusion and MIC quality control ranges for BC-3205 and BC-3781, two novel pleuromutilin antibiotics.

Ross JE, Sader HS, Ivezic-Schoenfeld Z, Paukner S, Jones RN.

J Clin Microbiol. 2012 Oct;50(10):3361-4. doi: 10.1128/JCM.01294-12. Epub 2012 Jul 18.

24.

LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers).

Flamm RK, Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN.

Diagn Microbiol Infect Dis. 2012 Sep;74(1):54-61. doi: 10.1016/j.diagmicrobio.2012.05.012. Epub 2012 Jun 15.

PMID:
22704791
25.

The effects of recreational sport on VO₂peak, VO₂ kinetics and submaximal exercise performance in males and females.

Edgett BA, Ross JE, Green AE, MacMillan NJ, Milne KJ, Gurd BJ.

Eur J Appl Physiol. 2013 Jan;113(1):259-66. doi: 10.1007/s00421-012-2435-4. Epub 2012 Jun 9.

PMID:
22684371
26.

Exercise intensity of recreational sport: impacts of sex and fitness.

Boyd CJ, Macmillan NJ, Green AE, Ross JE, Thorp DB, Gurd BJ.

J Sports Sci Med. 2012 Sep 1;11(3):562-3. eCollection 2012. No abstract available.

27.

Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor.

Ross JE, Scangarella-Oman NE, Miller LA, Sader HS, Jones RN.

J Clin Microbiol. 2011 Nov;49(11):3928-30. doi: 10.1128/JCM.01213-11. Epub 2011 Sep 14.

28.

Major depression among methamphetamine users entering drug treatment programs.

McKetin R, Lubman DI, Lee NM, Ross JE, Slade TN.

Med J Aust. 2011 Aug 1;195(3):S51-5.

PMID:
21806520
29.

LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States.

Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN.

Antimicrob Agents Chemother. 2011 Aug;55(8):3684-90. doi: 10.1128/AAC.01729-10. Epub 2011 Jun 13.

30.

Determination of disk diffusion and MIC quality control guidelines for JNJ-Q2, a novel quinolone.

Ross JE, Liverman LC, Jones RN.

J Clin Microbiol. 2011 Aug;49(8):3009-11. doi: 10.1128/JCM.00636-11. Epub 2011 Jun 8.

31.

Eight-year (2002-2009) summary of the linezolid (Zyvox® Annual Appraisal of Potency and Spectrum; ZAAPS) program in European countries.

Ross JE, Farrell DJ, Mendes RE, Sader HS, Jones RN.

J Chemother. 2011 Apr;23(2):71-6. Review.

PMID:
21571621
32.

Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program.

Biedenbach DJ, Farrell DJ, Mendes RE, Ross JE, Jones RN.

Diagn Microbiol Infect Dis. 2010 Dec;68(4):459-67. doi: 10.1016/j.diagmicrobio.2010.09.018.

PMID:
21094428
33.

Gold-catalyzed cascade cyclization-oxidative alkynylation of allenoates.

Hopkinson MN, Ross JE, Giuffredi GT, Gee AD, Gouverneur V.

Org Lett. 2010 Nov 5;12(21):4904-7. doi: 10.1021/ol102061k.

PMID:
20936849
34.

Cardiac sudden death as a result of acute coronary artery thrombosis during chemotherapy for testicular carcinoma.

Panella M, Ross JE, Garvin K, Martin A.

J Forensic Sci. 2010 Sep;55(5):1384-8. doi: 10.1111/j.1556-4029.2010.01437.x. Epub 2010 Jul 12.

PMID:
20629911
35.

First report of Staphylococcal clinical isolates in Mexico with linezolid resistance caused by cfr: evidence of in vivo cfr mobilization.

Mendes RE, Deshpande L, Rodriguez-Noriega E, Ross JE, Jones RN, Morfin-Otero R.

J Clin Microbiol. 2010 Aug;48(8):3041-3. doi: 10.1128/JCM.00880-10. Epub 2010 Jun 2. No abstract available.

36.

In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp.

Biedenbach DJ, Ross JE, Putnam SD, Jones RN.

Antimicrob Agents Chemother. 2010 May;54(5):2273-5. doi: 10.1128/AAC.00090-10. Epub 2010 Mar 22. No abstract available.

37.

MIC quality control guidelines and disk diffusion test optimization for CEM-101, a novel fluoroketolide.

Jones RN, Ross JE, Rhomberg PR; Quality Control Working Group.

J Clin Microbiol. 2010 Apr;48(4):1470-3. doi: 10.1128/JCM.01992-09. Epub 2009 Dec 30.

38.

Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.

Jones RN, Ross JE, Bell JM, Utsuki U, Fumiaki I, Kobayashi I, Turnidge JD.

Diagn Microbiol Infect Dis. 2009 Dec;65(4):404-13. doi: 10.1016/j.diagmicrobio.2009.10.001.

PMID:
19913683
39.

Linezolid surveillance program results for 2008 (LEADER Program for 2008).

Farrell DJ, Mendes RE, Ross JE, Jones RN.

Diagn Microbiol Infect Dis. 2009 Dec;65(4):392-403. doi: 10.1016/j.diagmicrobio.2009.10.011.

PMID:
19913682
40.

Daptomycin activity tested against linezolid-nonsusceptible gram-positive clinical isolates.

Mendes RE, Jones RN, Deshpande LM, Ross JE, Sader HS.

Microb Drug Resist. 2009 Dec;15(4):245-9. doi: 10.1089/mdr.2009.0045.

PMID:
19857129
41.

ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries.

Jones RN, Kohno S, Ono Y, Ross JE, Yanagihara K.

Diagn Microbiol Infect Dis. 2009 Jun;64(2):191-201. doi: 10.1016/j.diagmicrobio.2009.03.001.

PMID:
19500528
42.

United States resistance surveillance results for linezolid (LEADER Program for 2007).

Jones RN, Ross JE, Castanheira M, Mendes RE.

Diagn Microbiol Infect Dis. 2008 Dec;62(4):416-26. doi: 10.1016/j.diagmicrobio.2008.10.010.

PMID:
19022153
43.

Proposed quality control ranges for 2-microg anidulafungin disk diffusion testing and ability of the method to detect strains with elevated echinocandin MIC values.

Jones RN, Ross JE, Sheehan DJ.

Diagn Microbiol Infect Dis. 2008 Dec;62(4):474-7. doi: 10.1016/j.diagmicrobio.2008.08.021. Epub 2008 Nov 5.

PMID:
18990524
44.
45.

LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).

Jones RN, Fritsche TR, Sader HS, Ross JE.

Diagn Microbiol Infect Dis. 2007 Nov;59(3):309-17. Epub 2007 Aug 27.

PMID:
17720350
46.

Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study.

Ross JE, Fritsche TR, Sader HS, Jones RN.

Int J Antimicrob Agents. 2007 Mar;29(3):295-301. Epub 2007 Jan 18.

PMID:
17239570
47.
48.

Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci.

Jones RN, Fritsche TR, Sader HS, Ross JE.

Antimicrob Agents Chemother. 2006 Jul;50(7):2583-6.

49.
50.

Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.

Jones RN, Ross JE, Fritsche TR, Sader HS.

J Antimicrob Chemother. 2006 Feb;57(2):279-87. Epub 2005 Dec 2.

PMID:
16326811

Supplemental Content

Support Center